Page 4 of 4, showing 41 records out of 191 total, starting on record 151, ending on 191
| Publication |
Category |
Year |
|
401. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Giguère, V., Tremblay, A., Tremblay, G. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 79: 213-225. |
Breast Cancer |
2001 |
|
403. Labrie, F., Simard, A.R., Labrie, C., Bélanger, A. (2001) EM-652 (SCH57068) a pure SERM in the mammary gland and endometrium. Référence en Gynécologie Obstétrique, 8: 331-336. |
Breast Cancer |
2001 |
|
404. Pelletier, G., El Alfy, M., Labrie, C., Martel, C., Labrie, F. (2001) Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and GnRH-treated female rats. Neuroendocrinology, 74: 367-374. |
Breast Cancer |
2001 |
|
406. Sauvé, F., McBroom, L.D.B., Gallant, J., Moraitis, A.N., Labrie, F., Giguère, V. (2001) CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol. Cell. Biol, 21: 343-353. |
Breast Cancer |
2001 |
|
34. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
Breast Cancer |
2002 |
|
393. Gutman, M., Couillard, S., Roy, J., Labrie, F., Candas, B., Labrie, C. (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 99: 273-278. |
Breast Cancer |
2002 |
|
395. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. |
Breast Cancer |
2002 |
|
396. Labrie, F., Labrie, C., Bélanger, A., Simard, J. (2002) Third and fourth generation SERMs, in: Manni, A. et Verderame, M., eds: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Totowa, NJ, Humana Press Inc., pp 167-187. |
Breast Cancer |
2002 |
|
387. Dimitrakakis, C., Zhou, J., Wang, J., Belanger, A., Labrie, F., Cheng, C., Powell, D., Bondy, C. (2003) A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause, 10: 292-298. |
Breast Cancer |
2003 |
|
388. Gutman, M., Couillard, C., Labrie, F., Candas, B., Labrie, C. (2003) Effect of treatment sequence with radiotherapy and the antiestrogen EM-800 on the growth of ZR-75-1 Human mammary carcinoma in nude mice. Int J Cancer, 103: 268-276. |
Breast Cancer |
2003 |
|
389. Jensen, J., Kitlen, J., Briand, P., Labrie, F., Lykkesfeldt, A.E. (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J. Steroid Biochem Mol Biol, 84: 469-78. |
Breast Cancer |
2003 |
|
390. Labrie, F., El Alfy, M., Berger, L., Labrie, C., Martel, C., Bélanger, A., Candas, B., Pelletier, G. (2003) The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology, 144: 4700-4706. |
Breast Cancer |
2003 |
|
391. Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., Pelletier, G. (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Reviews, 24 (2): 152-182. |
Breast Cancer |
2003 |
|
392. Roy, J., Couillard, C., Gutman, M., Labrie, F. (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat, 81: 223-229. |
Breast Cancer |
2003 |
|
386. Labrie, F., Champagne, P., Labrie, C., Roy, J., Laverdiere, J., Provencher, L., Potvin, M., Drolet, Y., Pollak, M., Panasci, L., L'Espérance, B., Dufresne, J., Latreille, J., Robert, E., Samson, B., Jolivet, J., Yelle, L., Cusan, L., Diamond, P., Candas, B. (2004) Activity and safety of the orally active precursor of EM-652 (Acolbifene) in Tamoxifen-resistant breast cancer. J Clin Oncol, 22: 864-871. |
Breast Cancer |
2004 |
|
385. Tchédam Ngatcha, B., Luu-The, V., Labrie, F., Poirier, D. (2005) Androsterone 3beta-Ether-3beta-Substituted and Androsterone 3beta-Substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship. J. Med. Chem., 48: 5257-5268. |
Breast Cancer |
2005 |
|
16. Labrie, F. (2006) Keyrole of endocrinology in the victory against prostate cancer. Bull. Cancer, 93: 949-58. |
Breast Cancer |
2006 |
|
380. Labrie, F. (2006) Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer, 13: 335-355. |
Breast Cancer |
2006 |
|
382. Liby, K., Rendi, M., Suh, N., Royce, D.B., Risingsong, R., Williams, C.R., Lamph, W., Labrie, F., Krajewsi, S., Xu, X., Kim, H., Brown, P., Sporn, M.B. (2006) The Combination of the Rexinoid, LG100268, and a SERM, either Arzoxifene or Acolbifene, Synergize in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor Negative Model of Breast Cancer. Clin Cancer Res, 12: 5902-5909. |
Breast Cancer |
2006 |
|
383. Luu-The, V., Tremblay, P., Labrie, F. (2006) Characterization of type 12 17beta-hydroxysteroid dehydrogenase (17beta-HSD12), an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Molecular Endocrinology (Baltimore, Md.), 20: 437-43. |
Breast Cancer |
2006 |
|
384. Song, D., Liu, G., Luu-The, V., Zhao, D., Wang, L., Zhang, H., Xueling, G., Li, S., Desy, L., Labrie, F., Pelletier, G. (2006) Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol, 101: 136-44. |
Breast Cancer |
2006 |
|
5. Akaza, H., Labrie, F., Namiki, M. (2007) [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]. Gan To Kagaku Ryoho. Jpn J Cancer Chemotherapy, 34: 657-669. |
Breast Cancer |
2007 |
|
355. Labrie, F. (2007) Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab, 3: 584-93. |
Breast Cancer |
2007 |
|
379. Liu, H., Zheng, S.F., Bellemare, V., Pelletier, G., Labrie, F., Luu-The, V. (2007) Expression and localization of estrogenic type 12 17beta-hydroxysteroid dehydrogenase in the cynomolgus monkey. BMC Biochem, 8: 2 |
Breast Cancer |
2007 |
|
373. Berger, L., El-Alfy, M., Labrie, F. (2008) Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat. J Steroid Biochem Mol Biol, 109: 67-80. |
Breast Cancer |
2008 |
|
374. Labrie, F. (2008) Combination of Breast Cancer Prevention with Tissue-Targeted Hormone Replacement Therapy, In: Breast Cancer - Prognosis, Treatment, and Prevention, Second Edition, Pasqualini, J.R., ed., pp. 201-252. |
Breast Cancer |
2008 |
|
376. Pelletier, G., Labrie, C., Martel, C., Labrie, F. (2008) Chronic administration of dehydroepiandrosterone (DHEA) to female monkey and rat has no effect on mammary gland histology. J Steroid Biochem Mol Biol, 108: 102-108. |
Breast Cancer |
2008 |
|
725. Labrie, F., Koutsilieris, M. (2008) The 12th International Congress on Hormonal Steroids and Hormones & Cancer. J Steroid Biochem Mol Biol, 108: 179. |
Breast Cancer |
2008 |
|
4691. Han, B., Li, S., Song, D., Poisson-Paré, D., Liu, G., Luu-The, V., Ouellet, J., Li, S., Labrie, F., Pelletier, G. (2008) Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters. J Steroid Biochem Mol Biol, 112: 194-200 |
Breast Cancer |
2008 |
|
353. Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. (2009) Effect of One-Week Treatment with Vaginal Estrogen Preparations on Serum Estrogen Levels in Postmenopausal Women. Menopause, 16: 30-36. |
Breast Cancer |
2009 |
|
4698. Li, Z., Luu-The, V., Poisson-Paré, D., Ouellet, J., Li, S., Labrie, F., Pelletier, G. (2009) Expression of enzymes involved in synthesis and metabolism of estradiol in human breast as studied by immunocytochemistry and in situ hybridization. Histol Histopathol, 24: 273-282. |
Breast Cancer |
2009 |
|
4700. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Balser, J. (2009) Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women, Menopause, 16: 923-931. |
Breast Cancer |
2009 |
|
4701. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Martel, C., Balser, J. (2009) Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy, Menopause, 16: 907-922. |
Breast Cancer |
2009 |
|
4702. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Martel, C., Balser, J. (2009) Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration, Menopause, 16: 897-906. |
Breast Cancer |
2009 |
|
4705. Labrie, F., Martel, C. (2009) Concurrent hormone and radiation therapy in patients with breast cancer: how does chemotherapy affect treatment? The Lancet - Reflection and Reaction, 10: 444-445 |
Breast Cancer |
2009 |
|
4712. Labrie, F., Martel, C., Gauthier, S., Pelletier, G., Sancéau JY. (2010) Effect of toremifene and ospemifene, compared to acolbifene, on estrogen-sensitive parameters in rat and human uterine tissues, Horm Mol Biol Clin Invest, 1: 139-146. |
Breast Cancer |
2010 |
|
4733.
Li, S., Han, B., Liu, G., Li, S., Ouellet, J., Labrie, F., Pelletier, G. (2010) Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland. J Histochem Cytochem. 58:509-15.
|
Breast Cancer |
2010 |
|
4761. Zhao, G., Lu, L., Luu-The, V., Fan, Z., Labrie, F., Pelletier, G. (2010) Expression of 5alpha-reductase type 1 in breast cancer and adjacent non-malignant tissue: an immunohistochemical study. Horm Mol Biol Clin Invest. 3:411-415. |
Breast Cancer |
2010 |
|
4755. Lu, L., Zhao, G., Luu-The, V., Ouellet, J., Fan, Z., Labrie, F., Pelletier, G. (2011) Expression of 11β-hydroxysteroid dehydrogenase Type 1 in breast cancer and adjacent non-malignant tissue. An immunocytochemical study. Pathol Oncol Res. 17:627-632. |
Breast Cancer |
2011 |
|
4754. Labrie, F (2011) DHEA and Cancer Risk or Prevention? In: DHEA (Dehydroepiandrosterone) in Human Health and Aging, R.R.Watson ed., Taylor & Francis Group LLC, publishers, Chapter 12, pp: 153-172. |
Breast Cancer |
2011 |
|
4763. Labrie, F. (2011) Editorial: The major role of androgens in prostate cancer and the need for more efficient blockade. Expert Rev. Endocrinol. Metab. 6:313-316. |
Breast Cancer |
2011 |